Viridian Therapeutics Inc. (VRDN)
NASDAQ: VRDNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 18.89 +1.24%
VRDN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.11B
- EPS (TTM)
- -$3.39
- Dividend yield
- None
- 52-week range
- 13.18 – 34.29
- Day range
- 18.16 – 18.71
- Volume / Avg
- 1.33M / 1.71M
- Beta
- —
- Shares outstanding
- 113.29M
- Next earnings
- Nov 4, 2026
52-week range
VRDN stock today
Viridian Therapeutics (VRDN) closed at $18.66 on Oct 9, up 1.74% (+$0.32), versus the S&P 500's 0.59% gain. At this level, VRDN sits in the middle of its 52-week range of $13.18 to $34.29: 45.6% below the high, set on Jan 14, 2026 and 41.6% above the low. VRDN is down 41.1% year to date, underperforming the S&P 500 (+14.2%). Over the past 12 months, the stock has lost 14.1%.
Viridian Therapeutics has posted a net loss over the last twelve months (EPS of -$3.39), so its P/E ratio is not meaningful. Viridian Therapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Viridian Therapeutics
Company profileViridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Stephen F. Mahoney J.D., MBA
- Headquarters
- Waltham, MA
- Employees
- 252
- IPO year
- 2014
- Website
- viridiantherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Viridian Therapeutics generated $70.8 million in revenue, up 23359.9% from fiscal 2024. Viridian Therapeutics reported a net loss of $342.6 million, compared with a loss of $269.9 million a year earlier. Operating margin was -512.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $70.85M | $302.00K | $314.00K | $1.77M | $2.96M |
| Growth | +23359.93% | -3.82% | -82.28% | -40.20% | +182.19% |
| Net income | $-342.60M | $-269.95M | $-237.73M | $-129.87M | $-79.41M |
| EPS (diluted) | — | — | $-5.31 | $-4.05 | $-6.66 |
Analyst forecast
ForecastConsensus (17 analysts)
strong_buy
Avg. price target
$36.75+96.95%
- Strong buy 3
- Buy 14
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-1.08
- Last reported (Q3 2024)
- Nov 12, 2024
- EPS actual vs est.
- $-1.15 vs —
Viridian Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRGOPerrigo Company plc | 15.06 | +3.86% | $2.08B | vs VRDN |
| MLYSMineralys Therapeutics Inc. | 23.37 | +4.42% | $2.07B | vs VRDN |
| SDGRSchrodinger Inc. | 27.28 | +3.37% | $2.04B | vs VRDN |
| VERAVera Therapeutics Inc. Class A | 29.88 | +0.50% | $2.15B | vs VRDN |
| PVLAPalvella Therapeutics Inc. | 138.77 | +5.66% | $2.00B | vs VRDN |
| PHVSPharvaris N.V. | 31.10 | -0.06% | $2.18B | vs VRDN |
| LKFTLakefront Biotherapeutics ADR | 29.73 | +0.75% | $1.95B | vs VRDN |
| AUPHAurinia Pharmaceuticals Inc | 16.65 | +2.65% | $2.22B | vs VRDN |
Indexes, lists and sector
Viridian Therapeutics stock FAQ
What is Viridian Therapeutics's stock price today?
VRDN last traded at $18.66 as of Oct 9, 4:00 PM EDT, up 1.74% on the day. Prices are delayed at least 15 minutes.
Does Viridian Therapeutics pay a dividend?
No. Viridian Therapeutics does not currently pay a regular cash dividend.
When is Viridian Therapeutics's next earnings date?
Viridian Therapeutics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-1.08.
Who is Viridian Therapeutics's CEO?
Mr. Stephen F. Mahoney J.D., MBA is the chief executive officer of Viridian Therapeutics Inc., which has about 252 employees.
Has VRDN ever split its stock?
Yes. The most recent VRDN stock split was a 1-for-15 split on Nov 13, 2020, one of 2 splits on record.
What is the VRDN 52-week high?
The 52-week high for VRDN is $34.29 and the 52-week low is $13.18. The stock is currently 45.6% below its high.